Previous 10 | Next 10 |
Accolade ( NASDAQ: ACCD ) stock rose ~23% on Tuesday after FQ3 2023 revenue grew 9% Y/Y and the company provided outlook for fiscal '23 and '24. FQ3 revenue increased to $90.95M, compared to $83.45M in FQ3 fiscal 2022. GAAP EPS of -$0.56, compared to $0.31 in the...
Accolade, Inc. (ACCD) Q3 2023 Earnings Conference Call January 09, 2023 04:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investo...
The following slide deck was published by Accolade, Inc. in conjunction with their 2023 Q3 earnings call. For further details see: Accolade, Inc. 2023 Q3 - Results - Earnings Call Presentation
Accolade press release ( NASDAQ: ACCD ): FQ3 GAAP EPS of -$0.56 beats by $0.06 . Revenue of $90.9M (+8.9% Y/Y) beats by $3.37M . Sees Q4 revenue of $97M to $101M. The consensus revenue estimate is $101.71M. Sees Q4 adj. EBITDA between loss of $1M to earnings of...
Fiscal third quarter 2023 revenue of $90.9 million, a 9% increase compared to fiscal third quarter 2022 revenue of $83.5 million SEATTLE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2022....
Accolade ( NASDAQ: ACCD ) is scheduled to announce Q3 earnings results on Monday, January 9th, after market close. The consensus EPS Estimate is -$0.43 (-238.7% Y/Y) and the consensus Revenue Estimate is $87.53M (+4.9% Y/Y). Over the last 1 year, ACCD has beaten EPS estimate...
Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25 th Annual Needham Growth Conference on Wednesday, January 11, 2023 and will host a fireside chat at 1:30 pm ET. A webcast and replay of the fireside chat will be availab...
Summary Accolade went public in mid-2020, raising around $220 million in a U.S. IPO. The firm provides healthcare management capabilities to enterprises and other client types. ACCD has grown revenue but continues to generate significant operating losses. I'm on Hold for ACCD un...
SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes. In conjunction, the company w...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...